X4 Pharmaceuticals Inc
General ticker "XFOR" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $102.4M
X4 Pharmaceuticals Inc does not follow the US Stock Market performance with the rate: -23.8%.
Estimated limits based on current volatility of 9.4%: low 0.58$, high 0.70$
Factors to consider:
- Price in estimated range
- Earnings for 9 months up through Q3 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2023-12-31 to 2025-12-30
- 2023-12-31 to 2024-12-30 estimated range: [0.55$, 1.51$]
- 2024-12-30 to 2025-12-30 estimated range: [0.52$, 1.45$]
Financial Metrics affecting the XFOR estimates:
- Negative: Non-GAAP EPS, $ of -0.60 <= 0.10
- Negative: Operating profit margin, % of -100 <= 1.03
- Negative: negative Net income
- Negative: Operating cash flow per share per price, % of -41.72 <= 2.35
- Positive: Inventory ratio change, % of 0 <= 0
- Positive: Interest expense per share, $ of 0.03 <= 0.14
- Negative: Industry operating cash flow per share per price (median), % of -23.87 <= 3.85
Short-term XFOR quotes
Long-term XFOR plot with estimates
Financial data
| YTD | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.51MM | $0.00MM |
| Operating Expenses | $85.11MM | $88.08MM | $107.52MM |
| Operating Income | $-85.11MM | $-87.57MM | $-107.52MM |
| Non-Operating Income | $-3.57MM | $-6.27MM | $6.43MM |
| Interest Expense | $3.64MM | $3.99MM | $5.78MM |
| R&D Expense | $50.65MM | $61.06MM | $72.02MM |
| Income(Loss) | $-88.68MM | $-93.84MM | $-101.09MM |
| Taxes | $0.02MM | $0.03MM | $0.08MM |
| Profit(Loss) | $-88.70MM | $-93.87MM | $-101.17MM |
| Stockholders Equity | $64.41MM | $74.05MM | $51.10MM |
| Assets | $117.18MM | $155.59MM | $147.26MM |
| Operating Cash Flow | $-70.91MM | $-77.10MM | $-96.51MM |
| Capital expenditure | $0.61MM | $0.10MM | $0.06MM |
| Investing Cash Flow | $-0.61MM | $-0.10MM | $-14.88MM |
| Financing Cash Flow | $74.25MM | $117.23MM | $88.52MM |
| Earnings Per Share* | $-3.44 | $-1.48 | $-0.57 |
* EPS are Split Adjusted, recent splits may be reflected with a delay.